Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity

Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties

Antzelevitch, C. N., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Diego, J. M. D., Fish, J. M., Cordeiro, J. M., & Thomas, G. (2004) · Circulation · doi:10.1161/01.cir.0000139333.83620.5d · Cited by 674 · see citing works

Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

Wang, Z., Fermini, B., & Nattel, S. (1993) · Circulation Research · doi:10.1161/01.res.73.6.1061 · Cited by 576 · see citing works

Outward K + Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation

Wagoner, D. R. V., Pond, A. L., McCarthy, P. M., Trimmer, J. S., & Nerbonne, J. M. (1997) · Circulation Research · doi:10.1161/01.res.80.6.772 · Cited by 556 · see citing works

Regional and tissue specific transcript signatures of ion channel genes in the non‐diseased human heart

Gaborit, N., Bouter, S. L., Szüts, V., Varró, A., Escande, D., Nattel, S., & Demolombe, S. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.126714 · Cited by 518 · see citing works

Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation

Olson, T. M., Alekseev, A. E., Liu, X., Park, S., Zingman, L. V., Bienengraeber, M., Sattiraju, S., Ballew, J. D., Jahangir, A., & Terzic, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl143 · Cited by 491 · see citing works

Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation

Burashnikov, A., Diego, J. M. D., Zygmunt, A. C., Belardinelli, L., & Antzelevitch, C. N. (2007) · Circulation · doi:10.1161/circulationaha.107.704890 · Cited by 399 · see citing works

Comparison of potassium currents in rabbit atrial and ventricular cells.

Giles, W. R., & Imaizumi, Y. (1988) · The Journal of Physiology · doi:10.1113/jphysiol.1988.sp017325 · Cited by 380 · see citing works

Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation

Wettwer, E., Hála, O., Christ, T., Heubach, J., Dobrev, D., Knaut, M., Varró, A., & Ravens, U. (2004) · Circulation · doi:10.1161/01.cir.0000145155.60288.71 · Cited by 295 · see citing works

Differences between outward currents of human atrial and subepicardial ventricular myocytes.

Amos, G. J., Wettwer, E., Metzger, F., Li, Q., Himmel, H. M., & Ravens, U. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021194 · Cited by 241 · see citing works

Innovative approaches to anti-arrhythmic drug therapy

Nattel, S., & Carlsson, L. G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2112 · Cited by 209 · see citing works

“Early” Class III Drugs for the Treatment of Atrial Fibrillation

Blaauw, Y., Gögelein, H., Tieleman, R. G., van Hunnik, A., Schotten, U., & Allessie, M. A. (2004) · Circulation · doi:10.1161/01.cir.0000143050.22291.2e · Cited by 173 · see citing works

Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications

Ravens, U., & Wettwer, E. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq398 · Cited by 133 · see citing works

Pathology‐specific effects of the I Kur / I to / I K,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation

Christ, T., Wettwer, E., Voigt, N., Hála, O., Radicke, S., Matschke, K., Varró, A., Dobrev, D., & Ravens, U. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.209 · Cited by 121 · see citing works

Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

Fedida, D. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.519 · Cited by 108 · see citing works

AZD7009:

Goldstein, R. N., Khrestian, C. M., Carlsson, L. G., & Waldo, A. L. (2004) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2004.04354.x · Cited by 108 · see citing works

New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value

Ford, J. W., & Milnes, J. T. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181719b0c · Cited by 93 · see citing works

Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigs

WIRTH, K. J. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00543-1 · Cited by 93 · see citing works

Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels

G�gelein, H., Brendel, J., Steinmeyer, K., Str�bing, C., Picard, N., Rampe, D., Kopp, K., Busch, A. E., & Bleich, M. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0957-y · Cited by 90 · see citing works

Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation

Yang, T., Yang, P., Roden, D. M., & Darbar, D. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.05.032 · Cited by 82 · see citing works

Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences

Feng, J., Xu, D., Wang, Z., et al. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.275.5.h1717 · Cited by 80 · see citing works

Mechanism of Action of the Antiarrhythmic Agent AZD7009

Persson, F. (2007) · Gothenburg University Publications Electronic Archive (Gothenburg University) · doi:10.1046/j.1540-8167.2005.40427.x · Cited by 73 · see citing works

Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation

Burashnikov, A., Diego, J. M. D., Sicouri, S., et al. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.09.015 · Cited by 72 · see citing works

Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect ofIKrandIKur/Itoblock

Burashnikov, A., Mannava, S., & Antzelevitch, C. N. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01242.2003 · Cited by 68 · see citing works

New developments in atrial antiarrhythmic drug therapy

Burashnikov, A., & Antzelevitch, C. N. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.245 · Cited by 64 · see citing works

Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange

Schotten, U., DEHAAN, S., Verheule, S., Harks, E. G. A., Frechen, D., Bodewig, E., Greiser, M., Ram, R., Maessen, J. G., & Kelm, M. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.11.024 · Cited by 64 · see citing works

Mechanisms of atrial-selective block of Na+ channels by ranolazine: I. Experimental analysis of the use-dependent block

Zygmunt, A. C., Nesterenko, V. V., Rajamani, S., Hu, D., Barajas-Martínez, H., Belardinelli, L., & Antzelevitch, C. N. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00242.2011 · Cited by 59 · see citing works

Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat

Blaauw, Y., Schotten, U., VANHUNNIK, A., Neuberger, H., & Allessie, M. A. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.021 · Cited by 56 · see citing works

Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre

Persson, F., Andersson, B., Duker, G., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.040 · Cited by 55 · see citing works

In Vitro and In Vivo Effects of the Atrial Selective Antiarrhythmic Compound AVE1231

WIRTH, K. J., Brendel, J., Steinmeyer, K., Linz, D., Rütten, H., & Gögelein, H. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318032002f · Cited by 55 · see citing works

Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel

Barajas-Martínez, H., Hu, D., Cordeiro, J. M., Wu, Y., Kovacs, R. J., Meltser, H., Hong, K., Burashnikov, E., Brugada, R., Antzelevitch, C. N., et al. (2008) · Circulation Research · doi:10.1161/circresaha.108.172619 · Cited by 55 · see citing works

Can inhibition of IKur promote atrial fibrillation?

Burashnikov, A., & Antzelevitch, C. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.05.020 · Cited by 52 · see citing works

Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel

Burashnikov, A., Pourrier, M., Gibson, J. K., et al. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.968305 · Cited by 48 · see citing works

Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog

Carlsson, L. G., Chartier, D., & Nattel, S. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000196242.04384.c3 · Cited by 45 · see citing works

The repolarization-excitability relationship in the human right atrium is unaffected by cycle length, recording site and prior arrhythmias

Bode, F., Kilborn, M. J., Karasik, P., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01189-x · Cited by 44 · see citing works

Atrial-Selective Sodium Channel Block Strategy to Suppress Atrial Fibrillation: Ranolazine versus Propafenone

Burashnikov, A., Belardinelli, L., & Antzelevitch, C. N. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.186395 · Cited by 43 · see citing works

Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs

Pandit, S. V., Zlochiver, S., Filgueiras‐Rama, D., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq359 · Cited by 42 · see citing works

Atrial-selective sodium channel block for the treatment of atrial fibrillation

Burashnikov, A., & Antzelevitch, C. N. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902997939 · Cited by 39 · see citing works

Dose-Dependence of 4-Aminopyridine Plasma Concentrations and Electrophysiological Effects in Dogs

Nattel, S., Matthews, C., Blasio, E. D., et al. (2000) · Circulation · doi:10.1161/01.cir.101.10.1179 · Cited by 36 · see citing works

Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.

Knobloch, K., Brendel, J., Rosenstein, B., Bleich, M., Busch, A. E., & WIRTH, K. J. (2004) · PubMed · Cited by 33 · see citing works

Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block

Oros, A., Volders, P. G. A., Beekman, J. D. M., van der Nagel, T., & Vos, M. A. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.07.017 · Cited by 33 · see citing works

Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2 H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure

Regan, C. P., Kiss, L., Stump, G. L., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127654 · Cited by 31 · see citing works

Effect of Atrial Electrical Remodeling on the Efficacy of Antiarrhythmic Drugs: Comparison of Amiodarone with IKr‐ and Ito/IKur‐Blockade In Vivo

Linz, D., Afkham, F., Itter, G., Rütten, H., & WIRTH, K. J. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.00962.x · Cited by 30 · see citing works

AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog

Burashnikov, A., Zygmunt, A. C., Diego, J. M. D., et al. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e0bc6b · Cited by 27 · see citing works

Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro

Löfberg, L., Jacobson, I., & Carlsson, L. G. (2006) · EP Europace · doi:10.1093/europace/eul061 · Cited by 24 · see citing works

Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations

Sicouri, S., Pourrier, M., Gibson, J. K., Lynch, J. J., & Antzelevitch, C. N. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.10.021 · Cited by 21 · see citing works

How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Antzelevitch, C., & Burashnikov, A. (2008) · Journal of Atrial Fibrillation · doi:10.4022/jafib.v1i1.400 · Cited by 19 · see citing works

Atrial Selective Effects of Intravenously Administered Vernakalant in Conscious Beagle Dogs

Bechard, J., & Pourrier, M. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31821b8608 · Cited by 8 · see citing works

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418 · see citing works

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403 · see citing works

Interaction between prolongation of repolarization and sodium channel blockade produces enhanced prolongation of refractoriness and greater use-dependent block

Li, W., & Duff, H. J. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)92120-b

Dauricine-induced changes in monophasic action potentials and effective refractory period of rabbit left ventricle in situ.

Xia, J.-S., Li, Z., Dong, J.-W., et al. (2002) · PubMed · Cited by 20 · see citing works

Concealed conduction in nodal dual pathways: Depressed conduction, prolonged refractoriness, or reset excitability cycle?

Xu, B., Billette, J., & Lavallée, M. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2005.11.011 · Cited by 14 · see citing works

Memantine: Suppression of High Frequency Action Potentials is caused by Prolongation of the Sodium Current Refractory Period

Netzer, R., Binscheck, T., Koch, R., et al. (1991) · Springer eBooks · doi:10.1007/978-3-642-46732-5_48 · Cited by 2 · see citing works

Role of the Atrium in Determining the Functional and Effective Refractory Periods and the Conductivity of the Atrioventricular Transmission System

Ferrier, G. R., & Dresel, P. E. (1973) · Circulation Research · doi:10.1161/01.res.33.4.375 · Cited by 32 · see citing works